(Q35622836)

9 August 2017

1 reference

title

Interleukin-2 receptor-directed therapies for cutaneous lymphomas (English)

1 reference

9 August 2017

Francine M Foss

1

1 reference

9 August 2017

Thomas A Waldmann

series ordinal

2

1 reference

9 August 2017

publication date

1 December 2003

1 reference

Hematology / Oncology Clinics of North America

9 August 2017

published in

1 reference

9 August 2017

volume

17

1 reference

9 August 2017

issue

6

1 reference

9 August 2017

page(s)

1449-1458

1 reference

The interleukin (IL) 2 receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900110-2

7 January 2021

Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900110-2

7 January 2021

Sharing of the interleukin-2 (IL-2) receptor gamma chain between receptors for IL-2 and IL-4

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900110-2

7 January 2021

Interleukin-2 receptor gamma chain: a functional component of the interleukin-7 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900110-2

7 January 2021

Certified professionals: CD4(+)CD25(+) suppressor T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900110-2

7 January 2021

Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87).

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900110-2

7 January 2021

Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900110-2

7 January 2021

Trans-acting transcriptional activation of the long terminal repeat of human T lymphotropic viruses in infected cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900110-2

7 January 2021

A humanized antibody that binds to the interleukin 2 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900110-2

7 January 2021

Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha-emitting radionuclide, bismuth 213.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900110-2

7 January 2021

Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900110-2

7 January 2021

Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900110-2

7 January 2021

Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900110-2

7 January 2021

Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900110-2

7 January 2021

Retinoid regulation of interleukin-2 receptors on human T-cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900110-2

7 January 2021

Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900110-2

7 January 2021

Arginine butyrate increases the cytotoxicity of DAB(389)IL-2 in leukemia and lymphoma cells by upregulation of IL-2Rbeta gene

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900110-2

7 January 2021

10.1016/S0889-8588(03)00110-2

Identifiers

DOI

1 reference

9 August 2017

1 reference